Show Summary Details
Page of

Urinary sepsis: extended spectrum β‎-lactamase-producing E. coli 

Urinary sepsis: extended spectrum β‎-lactamase-producing E. coli
Urinary sepsis: extended spectrum β‎-lactamase-producing E. coli

Rishi Dhillon

, and Amber Arnold

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 12 July 2020

Antibiotic resistance in Gram-negative organisms is increasing. Empirical antibiotic prescribing policies are based on local epidemiology. This chapter highlights a case of urinary sepsis due to an extended spectrum beta-lactamase (ESBL)-producing E. coli. The patient in the case is treated with the empirical antibiotic choice and dies. The microbiological identification and treatment of ESBL-producing organisms is discussed in reference to the correlation of in vitro susceptibility data with in vivo response. The role of beta-lactam-beta-lactamase inhibitor combinations (BLBLI) in vitro and the use of carbapenems for these organisms is discussed.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.